Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CYPHBullishIndustry Newsnews

High materiality8/10

DKK1 biomarker predicts sirexatamab benefit; Phase 3 path under discussion

Aug 12, 2026, 7:05 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Biomarker-defined efficacy signals and Fast Track designation can de-risk and de-risk the path to Phase 3; potential partner/licensing discussions and future funding could reassess valuation. ITT miss tempers enthusiasm, but consistent DKK1-driven gains in subgroups historically emphasize peak upside when Phase 3 confirms.

AI summary

What happened, with direct paths to the underlying reporting

Peer-reviewed DeFianCe results show baseline plasma DKK1 predicts greater sirexatamab benefit in second-line metastatic colorectal cancer, with higher DKK1 tied to better response and survival. While ITT PFS did not meet the primary endpoint, DKK1-high subgroups realized meaningful gains, supporting a biomarker-selected Phase 3 and Fast Track regulatory emphasis. Near-term catalysts include Q2 results and potential Phase 3 initiation, signaling upside for CYPH via Leap Therapeutics.

Peer-reviewed DeFianCe: baseline plasma DKK1 predicts sirexatamab benefit in 2L mCRC.
In DKK1-high patients, sirexatamab improves ORR, PFS, and OS.
ITT PFS not met; biomarker subgroups show strongest gains.
FDA Fast Track designation granted for DKK1-high regimen in May 2026.
Biomarker-driven Phase 3 planned; regulatory strategy outlined in Q2 results.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.